Unichem Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 506690 | NSE: UNICHEMLAB | Pharmaceuticals & Drugs | Small Cap

Unichem Lab Share Price

496 16.60 3.46%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Unichem Lab

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Unichem Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
3,439.3 Cr.
52-wk low:
271.7
52-wk high:
579.8

Is Unichem Laboratories Ltd an attractive stock to invest in?

1. Is Unichem Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unichem Laboratories Ltd is a below average quality company.

2. Is Unichem Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Unichem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Unichem Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Unichem Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Unichem Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Unichem Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 14.4%7.2%11.1%-5.2%-6.3%0.2%-3.5%1.8%-2.4%-11.4%-
Value Creation
Index
0.0-0.5-0.2-1.4-1.5-1.0-1.3-0.9-1.2-1.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,0441,0911,2215766669689041,1249431,0721,353
Sales YoY Gr.-4.5%11.9%-52.8%15.6%45.3%-6.5%24.3%-16.1%13.7%-
Adj EPS 13.57.111.9-6.4-17.80.9-13.66.5-9.5-43.5-17.2
YoY Gr.--47.3%67.5%-153.6%NANA-1677.9%NA-244.9%NA-
BVPS (₹) 99.9104.3112.9124.3392.6387.6375.3382378336.9341.8
Adj Net
Profit
12364.8108-58.2-1256-95.545.9-66.5-306-121
Cash Flow from Ops. 86.988117141-66.3-251-41.8-32.6-158-117-
Debt/CF from Ops. 000.10-00-0.40-0.8-0.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.3%10%5.8%13.7%
Adj EPS -213.9%NANANA
BVPS14.5%-3%-3.5%-10.9%
Share Price 8.2% 20.6% 18% 73.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
14.3711-5.4-6.40.2-3.61.7-2.5-12.1-5.1
Op. Profit
Mgn %
17.59.713.5-5.4-19.1-5-9.98.5-4-8.70.9
Net Profit
Mgn %
11.75.98.9-10.1-18.80.6-10.64.1-7.1-28.6-8.9
Debt to
Equity
000000000.10-
Working Cap
Days
171183173419371298385344444421179
Cash Conv.
Cycle
597163181152122175154245243127

Recent Performance Summary

Sales growth is good in last 4 quarters at 30.79%

Return on Equity is Poor

Sales growth has been subdued in last 3 years 5.84%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Unichem Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) -17.2 2.1
TTM Sales (₹ Cr.) 1,353 1,675
BVPS (₹.) 341.8 354
Reserves (₹ Cr.) 2,393 2,478
P/BV 1.43 1.38
PE 0.00 236.09
From the Market
52 Week Low / High (₹) 271.65 / 579.80
All Time Low / High (₹) 1.50 / 579.80
Market Cap (₹ Cr.) 3,439
Equity (₹ Cr.) 14.1
Face Value (₹) 2
Industry PE 48.2

Management X-Ray of Unichem Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Unichem Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1,0441,0911,2215766669689041,1249431,072
Operating Expenses 8639901,0786348021,0299951,0299861,165
Manufacturing Costs157168170131164306293276266290
Material Costs328375396188275339311359325455
Employee Cost 147178210118147177205234251271
Other Costs 231268303197217207186160145149
Operating Profit 181101142-58-136-61-9195-44-93
Operating Profit Margin (%) 17.3%9.3%11.7%-10.1%-20.5%-6.3%-10.0%8.5%-4.6%-8.7%
Other Income 43202376310299474242
Interest 2222311129
Depreciation 433835394562717683106
Exceptional Items 410-4000000-113
Profit Before Tax 22081124-92-122-22-6466-87-279
Tax 431724-170-29-712-3121
Profit After Tax 17764100-76-1217-5654-55-300
PAT Margin (%) 16.9%5.9%8.2%-13.1%-18.2%0.7%-6.2%4.8%-5.9%-27.9%
Adjusted EPS (₹)19.57.111.1-8.3-17.31.0-8.07.7-7.9-42.6
Dividend Payout Ratio (%)41%28%18%-36%-29%400%-50%52%-51%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 9069471,0261,1292,7612,7282,6422,6902,6612,372
Share Capital 18181818141414141414
Reserves 8879281,0081,1112,7472,7142,6282,6762,6472,358
Minority Interest0000000000
Debt10810015010076
Long Term Debt000000008964
Short Term Debt1081001501112
Trade Payables151143190228212193208189157244
Others Liabilities 149132149144135109159241203193
Total Liabilities 1,2071,2221,3731,5033,1083,0303,0253,1193,1222,886

Fixed Assets

Gross Block6426844155366559391,0381,1281,3241,691
Accumulated Depreciation2492883371104154213282360455
Net Fixed Assets3943963814645517858258469631,236
CWIP 8611923324723690331568494148
Investments 120153111899791,04266852039041
Inventories186186201254208274316386461480
Trade Receivables211206265296232331323360381472
Cash Equivalents 412011106741912055899157
Others Assets168142173142229316357380334352
Total Assets 1,2071,2221,3731,5033,1083,0303,0253,1193,1222,886

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 8788117141-66-251-42-33-158-117
PBT 179811241323,249-19-6466-87-279
Adjustment 20365672-3,214-7-65072203
Changes in Working Capital -75-12-33-36-103-21825-148-148-41
Tax Paid -37-18-31-272-73040
Cash Flow From Investing Activity 35-62-87-1321,648-323-36-80106202
Capex 50-76-134-142-153-189-377-285-126-36
Net Investments 27-292712,480-147296187204237
Others -4244209-679144518292
Cash Flow From Financing Activity -98-47-39-9-930-45-21-4596-62
Net Proceeds from Shares 1100000000
Net Proceeds from Borrowing 00000000-10-26
Interest Paid -2-2-2-2-3-2-1-1-2-9
Dividend Paid -76-36-43-1-33-42-34-29-28-28
Others -20-106-7-894014-151351
Net Cash Flow 24-21-90653-619-98-1584423
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)20.616.9510.19-7.01-6.240.26-2.12.03-2.07-11.91
ROCE (%)25.789.0412.75-8.33-6.08-0.76-2.322.5-3.08-10.21
Asset Turnover Ratio0.90.910.950.40.290.320.30.370.30.36
PAT to CFO Conversion(x)0.491.381.17N/AN/A-35.86N/A-0.61N/AN/A
Working Capital Days
Receivable Days736970178145106132111143145
Inventory Days55625714412691119114164160
Payable Days173143153406292217235202194161

Unichem Laboratories Ltd Stock News

Unichem Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Unichem Lab on 28-Mar-2024 16:01 is ₹496.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Unichem Lab stood at ₹3,439.3.
The latest P/E ratio of Unichem Lab as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Unichem Lab as of 28-Mar-2024 16:01 is 1.43.
The 52-week high of Unichem Lab is ₹579.8 and the 52-week low is ₹271.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unichem Lab is ₹1,353 ( Cr.) .

About Unichem Laboratories Ltd

Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.

The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.

Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and Baddi (Himachal Pradesh).

The company’s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The manufacturing plants have also received ISO 9001:2000 and ISO 14001:2004 certifications for quality management.

Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.

Milestones

1944- Unichem was commissioned by Late Amrut Mody.

1952- The company forayed into exporting activities.

1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.

1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.

1963- The company entered co-marketing of formulations tie up with Uni Sankyo.

1968- Unichem set up a formulation plant at Ghaziabad.

1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.

1972- As an acknowledgement for Late Amrut Mody’s  pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.

1973- Unichem's research laboratory was recognised for Phd work by Bombay University. Unichem's R&D centre was recognised by Department of Science and Technology.

1976- The company set up a fine chemicals unit at Roha.

1978- Unichem commissioned its Roha bulk drug plant.

1979- The company received its first clearance from drug authorities for NEFEDIFINE.

1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in India.

1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).

1987- The company entered the animal health care business.

1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.

1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.

1997- The company’s formulation plant located at Goa was commissioned. It set up new corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1998- The company’s formulations plant located at Baddi was fully operational.

1997-2000- The company implemented BaaN ERP.

1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.

2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for Goa and Baddi Plants

2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at Bangalore that would conduct research work in Bio-technology

2002- It formed a joint venture in UK called Niche Generics.

2002-2003- The company divested its animal healthcare division. It established subsidiaries in South Africa and Brazil. The company also undertook modernization of formulations plant located at Ghaziabad.

2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.

2005- The company set up of new pharma technology development center located at Goa. Unichem Baddi Unit II plant was commissioned. It acquired API manufacturing unit at Pithampur

2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics, United Kingdom.

2007- Unikare division launched that catered to Dermatology and Allied therapies segment.

Future Strategies

Unichem will continue to work on the therapeutic segments and will develop cost effective processes for the existing molecules. It will also focus on develop new drug delivery systems and new products for international business.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.